Oral Medication My Reduce Lesions

There is hope that this new medicine will replace daily injections. Laquinimod has been in the pipeline for a while and study results have been out for a few months.

“These latest data show the rapid onset and sustainability of laquinimod efficacy in MS patients,” said Giancarlo Comi, M.D., University Vita-Salute San Raffaele, Scientific Institute San Raffaele, Milan, Italy, principal investigator of the study. “Just as exciting is the fact that, with increased number of patients exposed to laquinimod, we found no new risks or safety issues. This reinforces earlier results demonstrating the laquinimod safety profile. The MS community looks forward to future data as we continue enrolling patients in the laquinimod Phase III clinical program.”laquinimod

These new data from the extension study build upon the initial 36-week, Phase IIb study results published in The Lancet*, which demonstrated that once-daily, oral 0.6mg laquinimod significantly reduced MRI disease activity by a median of 60 percent, compared to placebo, and was well tolerated.

From MedicalNewsToday

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS

Oral laquinimod for multiple sclerosis granted fast track status by FDA

Tagged with

Leave a Reply

Your email address will not be published. Required fields are marked *

* Copy This Password *

* Type Or Paste Password Here *